PTO/SB/08a (06-09)

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/699,517
INFORMATION BIGGLOGUES			OUDE	Filing Date	October 31, 2003
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Kolker, Daniel E.
Sheet	1	of	2	Attorney Docket Number	015270-008920US

				U.S. PATENT DO	CUMENTS		
Exam		Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	
"""	lais	140.	Number Kind Code <sup>2 (#known)</sup>	WIWI-DB-1111	Applicant of Office Bosament	Figures Appear	
		249		01-20-0209	Erangione et al		***************************************
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	000000000000	251			Schank	000000000000000000000000000000000000000	000000000000000000000000000000000000000
	000000000000	252	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~			000000000000000000000000000000000000000	000000000000000000000000000000000000000
***************************************	************	950	<del>U3-0,940,135 B2</del>	<del>\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\</del>	Schenk et al.		***************************************
		254	US-2005/0123544 A1	06-09-2005	Schenk et al.		
200000000000000000000000000000000000000	00000000000	250		09-07-2004	Schenk	000000000000000000000000000000000000000	000000000000000000000000000000000000000
***************************************	************	248	LIS-2004/0197831 A1	10-07-2004	Weksler et al	***************************************	*************
		256	US-2003/0165496 A1	09-04-2003	Basi et al.		
		239	US 5,807,741	09-15-1998	Brown et al.		

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of U.S. Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (06-09)

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/699,517	
INFORMATION DISCLOSURE				Filing Date	October 31, 2003	
STATEMENT BY APPLICANT			ANT	First Named Inventor	Schenk, Dale B.	
				Art Unit	1649	
(Use as many sheets as necessary)				Examiner Name	Kolker, Daniel E.	
Sheet	2	of	2	Attorney Docket Number	015270-008920US	

	0:4-	NON PATENT LITERATURE DOCUMENTS  Lively de page of the grather (in CARITAL LETTERS) title of the article (when appropriate) title of	T
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	1
	·	ALVES DA COSTA "Recent Advances on α-Synuclein Cell Biology : Functions and	L
	240	Dysfunctions," Current Molecular Medicines, 3:17-24 (2003).	
	241	CASADESUS et al., "The Estrogen Myth; Potential Use of Gonadotropin-releasing hormone Agonists for Treatment of Alzheimer's Disease," Drugs R&D, 7(3):187-193 (2006).	
	242	JANEWAY et al., <i>Immunology</i> , 3 <sup>rd</sup> edition, 8:18-8:19 (1997).	
	255	PCT Search report of 04/07/2009 for application PCT/US08/02392	
	243	PERRIN et al., "Epitope mapping and specificity of the anti-α-synuclein monoclonal antibody Syn-1 in mouse brain and cultured cell lines," <u>Neuroscience Letters</u> , 349:1331-1335 (2003), abstract only.	
	244	SIDHU et al., "Does α-synuclein modulate dopaminergic sybaptic content and tone at the	l٢
000000000000000000000000000000000000000	000000000000000000000000000000000000000	synapse, FASEB, 16:637-647 (2004):	000000
	245	SPILLANTINI et al., "α-Synuclein in Lewy bodies," Nature, 388:839-840 (1997).	
	246	TAKEDA et al., "Abnormal Accumulation of NACP/ α-Synuclein in Neurodegenerative Disorders," American Journal of Pathology, 152:367-372 (1998).	
	247	TOFARIS et al., "Physiological and Pathological Properties of α-synuclein," Cellular and Molecular Life Sciences, pp. 1-8 (2007).	

		<del></del>	
Examiner Signature	/Daniel Kolker/	Date Considered	11/04/2009

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.